Heidelberg Pharma AG

Regulatory Filings • Nov 17, 2009

News Details

Ad-hoc | 17 November 2009 08:50

WILEX AG: WILEX starts Phase I trial for WX-554 and thereby achieves second milestone of the strategic alliance with UCB

WILEX AG / Research Update

17.11.2009

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX starts Phase I trial for WX-554 and thereby achieves second milestone
of the strategic alliance with UCB

Munich, 17 November 2009. The biopharmaceutical company WILEX AG (ISIN
DE0006614720 / Frankfurt Stock Exchange / Prime Standard) was informed
today by the clinical Phase I Unit that the first dose in man has been
administered in the clinical trial with the mitogen-activated protein
kinase (MEK) inhibitor WX-554. The MEK inhibitor is part of the strategic
alliance with UCB Pharma S.A., Brussels, Belgium. The start of this trial
signals the second milestone, which leads to a milestone payment of EUR 5
million to WILEX by UCB.

The open-label dose escalation study in healthy male volunteers
investigates pharmacokinetics, pharmacodynamics as well as safety and
tolerability of WX-554. The trial aims to determine the optimal biological
dose for the inhibition of the MEK-system by WX-554.

End of Ad-hoc release

Important notes
This Ad-hoc release does not constitute either an offer to sell or an
invitation to buy securities. In particular, this document does not
constitute an offer to sell securities or a solicitation of an offer to buy
securities in the United States of America. The shares of WILEX AG (the
'Shares') may not be offered or sold in the United States of America or to
or for the account or benefit of 'U.S. persons' (as defined in Regulation S
under the U.S. Securities Act of 1933, as amended (the 'Securities Act')),
unless they have been registered or are exempt from registration under the
Securities Act. The Shares have not been and will not be registered under
the Securities Act. There will be no public offer of Shares in the United
States of America.

Contact
WILEX AG
Katja Arnold (CIRO)
Investor & Public Relations
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors@wilex.com

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

17.11.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---